Price T Rowe Associates Inc. MD Acquires 336,976 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Price T Rowe Associates Inc. MD increased its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 23.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,781,926 shares of the biotechnology company’s stock after purchasing an additional 336,976 shares during the period. Price T Rowe Associates Inc. MD owned approximately 3.06% of Ascendis Pharma A/S worth $269,374,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Avoro Capital Advisors LLC boosted its holdings in Ascendis Pharma A/S by 5.6% during the first quarter. Avoro Capital Advisors LLC now owns 3,966,666 shares of the biotechnology company’s stock valued at $599,641,000 after acquiring an additional 211,111 shares during the period. Capital International Investors boosted its holdings in Ascendis Pharma A/S by 0.5% during the first quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock valued at $331,261,000 after acquiring an additional 10,044 shares during the period. Nan Fung Group Holdings Ltd bought a new stake in Ascendis Pharma A/S during the first quarter valued at about $2,056,000. Bessemer Group Inc. boosted its holdings in Ascendis Pharma A/S by 61.0% during the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock valued at $132,000 after acquiring an additional 332 shares during the period. Finally, Acadian Asset Management LLC boosted its holdings in Ascendis Pharma A/S by 1,461.1% during the first quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock valued at $37,849,000 after acquiring an additional 234,446 shares during the period.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ASND. TD Cowen upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating and increased their target price for the company from $156.00 to $175.00 in a research note on Tuesday, June 25th. JPMorgan Chase & Co. raised their price objective on shares of Ascendis Pharma A/S from $167.00 to $170.00 and gave the company an “overweight” rating in a research note on Friday, May 3rd. StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Thursday, May 23rd. Morgan Stanley raised their price objective on shares of Ascendis Pharma A/S from $116.00 to $140.00 and gave the stock an “equal weight” rating in a report on Thursday, May 16th. Finally, Wells Fargo & Company boosted their price objective on shares of Ascendis Pharma A/S from $260.00 to $262.00 and gave the stock an “overweight” rating in a research note on Friday, May 3rd. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $179.00.

Ascendis Pharma A/S Trading Down 0.5 %

Ascendis Pharma A/S stock traded down $0.63 during trading hours on Friday, reaching $133.75. 175,736 shares of the stock were exchanged, compared to its average volume of 261,371. The stock has a 50 day moving average of $132.83 and a two-hundred day moving average of $139.23. Ascendis Pharma A/S has a twelve month low of $85.29 and a twelve month high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Thursday, May 2nd. The biotechnology company reported ($2.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.57) by ($0.91). Ascendis Pharma A/S had a negative net margin of 152.68% and a negative return on equity of 16,574.15%. The business had revenue of $103.11 million during the quarter, compared to analyst estimates of $85.72 million. On average, analysts forecast that Ascendis Pharma A/S will post -5.53 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.